{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T20:54:02Z","timestamp":1776372842525,"version":"3.51.2"},"reference-count":136,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Classic Hodgkin lymphoma (cHL) is one of the most common lymphomas in the Western world. Advances in the management of cHL have led to high cure rates exceeding 80%. Nevertheless, relapse or refractory disease in a subset of patients and treatment-related toxicity still represents unsolved clinical problems. The introduction of targeted treatments such as PD-1 blockade and the CD30 antibody drug conjugate, brentuximab vedotin, has broadened treatment options in cHL, emphasizing the critical need to identify biomarkers with the goal to provide rationales for treatment selection, increase effective drug utilization, and minimize toxicity. The unique biology of cHL featuring low abundant tumor cells and numerous nonmalignant immune cells in the tumor microenvironment can provide various types of promising biomarkers related to the tumor cells directly, tumor microenvironment cross-talk, and host immune response. Here, we comprehensively review novel biomarkers including circulating tumor DNA and gene expression\u2013based prognostic models that might guide the ideal management of cHL in the future.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000334","type":"journal-article","created":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T09:55:42Z","timestamp":1538646942000},"page":"206-214","source":"Crossref","is-referenced-by-count":14,"title":["Novel Biomarker Approaches in Classic Hodgkin Lymphoma"],"prefix":"10.1097","volume":"24","author":[{"given":"Tomohiro","family":"Aoki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Steidl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20230924","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.3109\/10428194.2010.525724","article-title":"Comparing adult and pediatric Hodgkin lymphoma in the Surveillance, Epidemiology and End Results Program, 1988\u20132005: an analysis of 21 734 cases","volume":"51","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"bib2-20230924","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","year":"2016","journal-title":"Blood"},{"key":"bib3-20230924","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7","article-title":"Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP","volume":"36","year":"1975","journal-title":"Cancer"},{"key":"bib4-20230924","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting","volume":"7","year":"1989","journal-title":"J Clin Oncol"},{"key":"bib5-20230924","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial","volume":"28","year":"2010","journal-title":"J Clin Oncol"},{"key":"bib6-20230924","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","year":"2010","journal-title":"N Engl J Med"},{"key":"bib7-20230924","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1182\/blood-2014-07-537480","article-title":"Risk assessment in the management of newly diagnosed classical Hodgkin lymphoma","volume":"125","year":"2015","journal-title":"Blood"},{"key":"bib8-20230924","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.2000.18.3.498","article-title":"Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment","volume":"18","year":"2000","journal-title":"J Clin Oncol"},{"key":"bib9-20230924","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.2000.18.3.487","article-title":"Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood","volume":"18","year":"2000","journal-title":"J Clin Oncol"},{"key":"bib10-20230924","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","year":"2007","journal-title":"Blood"},{"key":"bib11-20230924","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"bib12-20230924","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.2016.70.9709","article-title":"Risk of second cancer in Hodgkin lymphoma survivors and influence of family history","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib13-20230924","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2015.63.3651","article-title":"Biomarker: predictive or prognostic?","volume":"33","year":"2015","journal-title":"J Clin Oncol"},{"key":"bib14-20230924","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.91.23.10962","article-title":"Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development","volume":"91","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib15-20230924","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1084\/jem.184.4.1495","article-title":"Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells","volume":"184","year":"1996","journal-title":"J Exp Med"},{"key":"bib16-20230924","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1172\/JCI95993","article-title":"Human CD30+ B cells represent a unique subset related to Hodgkin lymphoma cells","volume":"128","year":"2018","journal-title":"J Clin Invest"},{"key":"bib17-20230924","first-page":"2080","article-title":"Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells","volume":"61","year":"2001","journal-title":"Cancer Res"},{"key":"bib18-20230924","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood-2002-03-0839","article-title":"Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma","volume":"101","year":"2003","journal-title":"Blood"},{"key":"bib19-20230924","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1182\/blood-2009-12-257345","article-title":"Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome","volume":"116","year":"2010","journal-title":"Blood"},{"key":"bib20-20230924","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","year":"2011","journal-title":"Nature"},{"key":"bib21-20230924","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood-2012-06-439570","article-title":"Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma","volume":"120","year":"2012","journal-title":"Blood"},{"key":"bib22-20230924","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells","volume":"125","year":"2015","journal-title":"Blood"},{"key":"bib23-20230924","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","year":"2018","journal-title":"Blood"},{"key":"bib24-20230924","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2017-11-814913","article-title":"Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma","volume":"131","year":"2018","journal-title":"Blood"},{"key":"bib25-20230924","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.pathol.4.110807.092209","article-title":"Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma","volume":"4","year":"2009","journal-title":"Annu Rev Pathol"},{"key":"bib26-20230924","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/path.4459","article-title":"The Epstein-Barr virus and the pathogenesis of lymphoma","volume":"235","year":"2015","journal-title":"J Pathol"},{"key":"bib27-20230924","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/ijc.30473","article-title":"The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis","volume":"140","year":"2017","journal-title":"Int J Cancer"},{"key":"bib28-20230924","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/MOH.0000000000000155","article-title":"Genomic alterations underlying immune privilege in malignant lymphomas","volume":"22","year":"2015","journal-title":"Curr Opin Hematol"},{"key":"bib29-20230924","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.celrep.2015.10.008","article-title":"Genomic alterations in CIITA are frequent in primary mediastinal large B cell lymphoma and are associated with diminished MHC class II expression","volume":"13","year":"2015","journal-title":"Cell Rep"},{"key":"bib30-20230924","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2013-10-535443","article-title":"Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma","volume":"123","year":"2014","journal-title":"Blood"},{"key":"bib31-20230924","doi-asserted-by":"crossref","first-page":"13134","DOI":"10.1073\/pnas.0706017104","article-title":"The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma","volume":"104","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib32-20230924","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","year":"2010","journal-title":"Blood"},{"key":"bib33-20230924","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib34-20230924","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","year":"2012","journal-title":"Clin Cancer Res"},{"key":"bib35-20230924","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","year":"2014","journal-title":"Nature"},{"key":"bib36-20230924","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","year":"2016","journal-title":"Nature"},{"key":"bib37-20230924","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1073\/pnas.1705327114","article-title":"Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients","volume":"114","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib38-20230924","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.aaf0683","article-title":"Rescue of exhausted CD8 T cells by PD-1\u2013targeted therapies is CD28-dependent","volume":"355","year":"2017","journal-title":"Science"},{"key":"bib39-20230924","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2326-6066.CIR-16-0201","article-title":"Classical Hodgkin lymphoma with reduced \u03b22M\/MHC class I expression is associated with inferior outcome independent of 9p24.1 status","volume":"4","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"bib40-20230924","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological analysis reveals a PD-L1\u2013associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib41-20230924","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/S0140-6736(05)66780-3","article-title":"Association with HLA class I in Epstein-Barr-virus\u2013positive and with HLA class III in Epstein-Barr-virus\u2013negative Hodgkin's lymphoma","volume":"365","year":"2005","journal-title":"Lancet"},{"key":"bib42-20230924","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib43-20230924","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/blood-2018-04-843714","article-title":"Mass cytometry of Hodgkin lymphoma reveals a CD4+ exhausted T-effector and T-regulatory cell rich microenvironment","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib44-20230924","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","year":"2012","journal-title":"J Clin Oncol"},{"key":"bib45-20230924","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.bbmt.2015.07.018","article-title":"Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed\/refractory Hodgkin lymphoma","volume":"21","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"bib46-20230924","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","year":"2018","journal-title":"N Engl J Med"},{"key":"bib47-20230924","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1158\/1078-0432.CCR-16-1387","article-title":"Nivolumab in the treatment of Hodgkin Lymphoma","volume":"23","year":"2017","journal-title":"Clin Cancer Res"},{"key":"bib48-20230924","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1182\/blood.V128.22.1108.1108","article-title":"Pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: long-term efficacy from the phase 1b KEYNOTE-013 study","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib49-20230924","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood.V128.22.1107.1107","article-title":"Pembrolizumab in relapsed\/refractory classical Hodgkin lymphoma: primary end point analysis of the phase 2 KEYNOTE-087 study","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib50-20230924","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1182\/blood.V128.22.1110.1110","article-title":"Checkmate 205 update with minimum 12-month follow up: a phase 2 study of nivolumab in patients with relapsed\/refractory classical Hodgkin lymphoma","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib51-20230924","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"key":"bib52-20230924","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib53-20230924","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1182\/blood-2018-03-841262","article-title":"Prolonged remissions after anti\u2013PD-1 discontinuation in patients with Hodgkin lymphoma","volume":"131","year":"2018","journal-title":"Blood"},{"key":"bib54-20230924","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1182\/blood.V128.22.1106.1106","article-title":"Title: a phase I study with an expansion cohort of the combination of ipilimumab and nivolumab and brentuximab vedotin in patients with relapsed\/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN Cancer Research Group (E4412 arms D and E)","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib55-20230924","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1182\/blood.V126.23.585.585","article-title":"Preliminary safety and efficacy of the combination of brentuximab vedotin and ipilimumab in relapsed\/refractory hodgkin lymphoma: a trial of the ECOG-ACRIN Cancer Research Group (E4412)","volume":"126","year":"2015","journal-title":"Blood"},{"key":"bib56-20230924","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","year":"2018","journal-title":"Blood"},{"key":"bib57-20230924","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.2017.74.3179","article-title":"Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed Hodgkin lymphoma","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib58-20230924","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1146\/annurev.biochem.67.1.753","article-title":"TGF-beta signal transduction","volume":"67","year":"1998","journal-title":"Annu Rev Biochem"},{"key":"bib59-20230924","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"bib60-20230924","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor\u2013redirected lymphocytes","volume":"127","year":"2017","journal-title":"J Clin Invest"},{"key":"bib61-20230924","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial","volume":"23","year":"2017","journal-title":"Clin Cancer Res"},{"key":"bib62-20230924","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1158\/2159-8290.CD-16-0850","article-title":"Overcoming the immunosuppressive tumor microenvironment of Hodgkin lymphoma using chimeric antigen receptor T cells","volume":"7","year":"2017","journal-title":"Cancer Discov"},{"key":"bib63-20230924","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1309\/AJCP45LUYQSOKRVE","article-title":"Diagnostic usefulness of flow cytometry for immunophenotyping classical Hodgkin lymphoma","volume":"136","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"bib64-20230924","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR\u2013T-cell therapy","volume":"127","year":"2016","journal-title":"Blood"},{"key":"bib65-20230924","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1200\/JCO.2006.10.0917","article-title":"HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma","volume":"25","year":"2007","journal-title":"J Clin Oncol"},{"key":"bib66-20230924","doi-asserted-by":"crossref","first-page":"e1295202","DOI":"10.1080\/2162402X.2017.1295202","article-title":"HLA dependent immune escape mechanisms in B-cell lymphomas: implications for immune checkpoint inhibitor therapy?","volume":"6","year":"2017","journal-title":"Oncoimmunology"},{"key":"bib67-20230924","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/ijc.2910550523","article-title":"A CD16\/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo","volume":"55","year":"1993","journal-title":"Int J Cancer"},{"key":"bib68-20230924","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","year":"2015","journal-title":"Blood"},{"key":"bib69-20230924","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1200\/JCO.2012.42.5223","article-title":"Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes","volume":"30","year":"2012","journal-title":"J Clin Oncol"},{"key":"bib70-20230924","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3324\/haematol.2017.180554","article-title":"A phase II study of the oral JAK1\/JAK2 inhibitor ruxolitinib in advanced relapsed\/refractory Hodgkin lymphoma","volume":"103","year":"2018","journal-title":"Haematologica"},{"key":"bib71-20230924","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"bib72-20230924","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3109\/10428199909058482","article-title":"Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease","volume":"34","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"bib73-20230924","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/annonc\/mdi200","article-title":"Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma","volume":"16","year":"2005","journal-title":"Ann Oncol"},{"key":"bib74-20230924","first-page":"475","article-title":"The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease","volume":"91","year":"2006","journal-title":"Haematologica"},{"key":"bib75-20230924","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2005-06-2252","article-title":"FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma","volume":"107","year":"2006","journal-title":"Blood"},{"key":"bib76-20230924","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1002\/cncr.22276","article-title":"FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease","volume":"107","year":"2006","journal-title":"Cancer"},{"key":"bib77-20230924","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study","volume":"25","year":"2007","journal-title":"J Clin Oncol"},{"key":"bib78-20230924","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1182\/blood-2007-09-112128","article-title":"Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes","volume":"111","year":"2008","journal-title":"Blood"},{"key":"bib79-20230924","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1200\/JCO.2008.16.0861","article-title":"Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review","volume":"27","year":"2009","journal-title":"J Clin Oncol"},{"key":"bib80-20230924","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","year":"2015","journal-title":"N Engl J Med"},{"key":"bib81-20230924","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","year":"2016","journal-title":"N Engl J Med"},{"key":"bib82-20230924","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1182\/asheducation-2016.1.316","article-title":"Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet?","volume":"2016","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"bib83-20230924","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib84-20230924","first-page":"2790","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","year":"2018","journal-title":"Lancet"},{"key":"bib85-20230924","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 trial","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib86-20230924","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/blood-2017-04-773838","article-title":"Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation","volume":"131","year":"2018","journal-title":"Blood"},{"key":"bib87-20230924","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood-2017-06-788877","article-title":"Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib88-20230924","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00259-014-2973-6","article-title":"FDG PET\/CT imaging as a biomarker in lymphoma","volume":"42","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib89-20230924","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US Intergroup Trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose\u2013positron emission tomography imaging: Southwest Oncology Group S0816","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib90-20230924","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"bib91-20230924","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood-2015-11-679407","article-title":"PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study","volume":"127","year":"2016","journal-title":"Blood"},{"key":"bib92-20230924","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1158\/1078-0432.CCR-12-2693","article-title":"Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma","volume":"19","year":"2013","journal-title":"Clin Cancer Res"},{"key":"bib93-20230924","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1158\/1078-0432.CCR-13-1024","article-title":"Plasma microRNA are disease response biomarkers in classical Hodgkin lymphoma","volume":"20","year":"2014","journal-title":"Clin Cancer Res"},{"key":"bib94-20230924","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/bjh.14317","article-title":"Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin-1, sCD163 and sCD30 with TARC","volume":"175","year":"2016","journal-title":"Br J Haematol"},{"key":"bib95-20230924","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1158\/0008-5472.CAN-05-0100","article-title":"Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor","volume":"65","year":"2005","journal-title":"Cancer Res"},{"key":"bib96-20230924","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3324\/haematol.2011.050138","article-title":"Peripheral blood lymphocyte\/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma","volume":"97","year":"2012","journal-title":"Haematologica"},{"key":"bib97-20230924","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1634\/theoncologist.2015-0251","article-title":"Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens","volume":"21","year":"2016","journal-title":"Oncologist"},{"key":"bib98-20230924","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00277-018-3276-y","article-title":"Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy","volume":"97","year":"2018","journal-title":"Ann Hematol"},{"key":"bib99-20230924","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.bbmt.2014.08.016","article-title":"Serum thymus and activation-regulated chemokine level monitoring may predict disease relapse detected by PET scan after reduced-intensity allogeneic stem cell transplantation in patients with Hodgkin lymphoma","volume":"20","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"bib100-20230924","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","year":"2008","journal-title":"Nat Med"},{"key":"bib101-20230924","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","article-title":"Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia","volume":"120","year":"2012","journal-title":"Blood"},{"key":"bib102-20230924","first-page":"224ra24","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","year":"2014","journal-title":"Sci Transl Med"},{"key":"bib103-20230924","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","year":"2015","journal-title":"Blood"},{"key":"bib104-20230924","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","year":"2015","journal-title":"Lancet Oncol"},{"key":"bib105-20230924","first-page":"1659","article-title":"DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells","volume":"61","year":"2001","journal-title":"Cancer Res"},{"key":"bib106-20230924","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/bjh.13349","article-title":"Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach","volume":"169","year":"2015","journal-title":"Br J Haematol"},{"key":"bib107-20230924","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S2352-3026(14)00039-8","article-title":"Non-invasive detection of genomic imbalances in Hodgkin\/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study","volume":"2","year":"2015","journal-title":"Lancet Haematol"},{"key":"bib108-20230924","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3324\/haematol.2016.145102","article-title":"Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma","volume":"101","year":"2016","journal-title":"Haematologica"},{"key":"bib109-20230924","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib110-20230924","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/1097-0142(19850715)56:2<333::AID-CNCR2820560222>3.0.CO;2-0","article-title":"Macrophage-histiocytes in Hodgkin's disease. The relation of peanut-agglutinin-binding macrophage-histiocytes to clinicopathologic presentation and course of disease","volume":"56","year":"1985","journal-title":"Cancer"},{"key":"bib111-20230924","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1309\/NB3947K383DJ0LQ2","article-title":"The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T\/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression","volume":"128","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"bib112-20230924","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3324\/haematol.11702","article-title":"Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma","volume":"93","year":"2008","journal-title":"Haematologica"},{"key":"bib113-20230924","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.leukres.2013.03.021","article-title":"Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma","volume":"37","year":"2013","journal-title":"Leuk Res"},{"key":"bib114-20230924","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nbt1385","article-title":"Direct multiplexed measurement of gene expression with color-coded probe pairs","volume":"26","year":"2008","journal-title":"Nat Biotechnol"},{"key":"bib115-20230924","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1038\/sj.onc.1205418","article-title":"Gene expression profiling defines molecular subtypes of classical Hodgkin's disease","volume":"21","year":"2002","journal-title":"Oncogene"},{"key":"bib116-20230924","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1182\/blood-2005-12-5125","article-title":"Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma","volume":"108","year":"2006","journal-title":"Blood"},{"key":"bib117-20230924","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1182\/blood-2008-07-168096","article-title":"Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome","volume":"113","year":"2009","journal-title":"Blood"},{"key":"bib118-20230924","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkin's lymphoma","volume":"362","year":"2010","journal-title":"N Engl J Med"},{"key":"bib119-20230924","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.2012.43.4589","article-title":"Gene expression\u2013based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma","volume":"31","year":"2013","journal-title":"J Clin Oncol"},{"key":"bib120-20230924","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3324\/haematol.2010.033316","article-title":"Macrophages predict treatment outcome in Hodgkin's lymphoma","volume":"96","year":"2011","journal-title":"Haematologica"},{"key":"bib121-20230924","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/hon.2437_80","article-title":"Application of a gene expression\u2013based model in combination with FDG-PET imaging to predict treatment response in advanced Hodgkin lymphoma in the RATHL Study (CRUK\/07\/033)","volume":"35","year":"2017","journal-title":"Hematol Oncol"},{"key":"bib122-20230924","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/hon.2437_81","article-title":"The 23-gene gene expression\u2013based assay does not predict interim PET scan results after ABVD in advanced stage classical Hodgkin lymphoma in the US Intergroup S0816 trial","volume":"35","year":"2017","journal-title":"Hematol Oncol"},{"key":"bib123-20230924","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood.V77.10.2292.2292","article-title":"Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988","volume":"77","year":"1991","journal-title":"Blood"},{"key":"bib124-20230924","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/(SICI)1097-0142(19960915)78:6<1293::AID-CNCR18>3.0.CO;2-W","article-title":"Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients","volume":"78","year":"1996","journal-title":"Cancer"},{"key":"bib125-20230924","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1182\/blood.V96.4.1280","article-title":"Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group","volume":"96","year":"2000","journal-title":"Blood"},{"key":"bib126-20230924","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/annonc\/mdf228","article-title":"The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation","volume":"13","year":"2002","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"bib127-20230924","first-page":"112","article-title":"Prognostic factors and treatment outcome in patients with primary progressive and relapsed Hodgkin's disease","volume":"13","year":"2002","journal-title":"Ann Oncol"},{"key":"bib128-20230924","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/sj.bmt.1705544","article-title":"LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre","volume":"39","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"bib129-20230924","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/PAI.0b013e3181c7138b","article-title":"The role of cytotoxic and regulatory T cells in relapsed\/refractory Hodgkin lymphoma","volume":"18","year":"2010","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"bib130-20230924","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1093\/annonc\/mdu387","article-title":"Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"25","year":"2014","journal-title":"Ann Oncol"},{"key":"bib131-20230924","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","year":"2002","journal-title":"Lancet"},{"key":"bib132-20230924","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1200\/JCO.2017.72.7925","article-title":"Prognostic model to predict post-autologous stem-cell transplantation outcomes in classical Hodgkin lymphoma","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib133-20230924","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"bib134-20230924","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1182\/blood-2010-05-282756","article-title":"Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"116","year":"2010","journal-title":"Blood"},{"key":"bib135-20230924","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3324\/haematol.2011.056051","article-title":"Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and\/or refractory Hodgkin's lymphoma responding to prior salvage therapy","volume":"97","year":"2012","journal-title":"Haematologica"},{"key":"bib136-20230924","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/bjh.12824","article-title":"F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"165","year":"2014","journal-title":"Br J Haematol"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00130404-201809000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T05:11:30Z","timestamp":1695532290000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130404-201809000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":136,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000334","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}